PMPernille Rudebeck Mogensen

Pernille Rudebeck Mogensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pernille Rudebeck Mogensen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of an Insulin Bolus Calculator on Glycemic Control in Relation to Exercise—A Crossover Randomized Controlled Trial

    by Kenney Fehrenkamp Pedersen, Pernille Rudebeck Mogensen, Mikkel Thor Olsen, Gaspar Letnar, Maria Amlund Kunckel, Ditte Hjorth Laursen, Peter Lommer Kristensen

    Introduction: Exercise benefits individuals with type 1 diabetes (T1D) but is often hindered by the risk of hypoglycemia. While guidelines provide strategies to mitigate this risk, adherence to recommendations on exercise remains low. Bolus calculators, such as Hedia Diabetes Assistant (HDA), offer a potential way to address this challenge by integrating exercise-related insulin adjustments into daily routines. This trial evaluates the safety and efficacy of HDA in improving glycemic control during exercise. Methods: This randomized, controlled crossover pilot study included 20 adults diagnosed with T1D for >1 year using multiple daily insulin injections and HbA1c between 42 and 72 mmol/mol (6.0–8.6%). Participants were randomized to first use either HDA (arm A) or their habitual diabetes management (arm B) before and after performing a 45-min moderate-intensity session on an exercise bike and subsequently crossover. The primary outcome was change in time in range (TIR) over the two 24 h periods. Results: The mean differences (95% confidence interval [CI]) in TIR and time above range (>10.0 mmol/L) were −2.3% (−13.1%, 8.5%) and 3.93% (−5.7%, 13.5%), respectively, and the median difference in time below range (<3.9 mmol/L) was −0.87% (−2.8%, 0.5%). The incidence rate ratio (95% CI) for total hypoglycemic episodes using HDA was −0.56 (−1.41, 0.29). Safety outcomes revealed fewer adverse events when using HDA. Conclusion: The HDA insulin bolus calculator with an integrated exercise feature appears safe to use when compared with habitual insulin management in people with T1D during moderate-intensity exercise.


  • Open Access

    Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols

    by Christina Egnell, Susanna Ranta, Joanna Banerjee, Andrea Merker, Riitta Niinimäki, Bendik Lund, Pernille Rudebeck Mogensen, Ólafur G. Jonsson, Goda Vaitkeviciene, Kristi Lepik, et al.

    Objectives: High body mass index (BMI) is associated with poorer survival in childhood acute lymphoblastic leukemia (ALL), but the actual impact on the risk of relapse still needs to be clarified. We evaluated the impact of BMI at diagnosis on the risk of relapse in children with ALL treated according to Nordic Society of Paediatric Haematology and Oncology (NOPHO) protocols.Method: In a multicenter study, we collected data on BMI at diagnosis and outcome of 2558 children aged 2.0‐17.9 years diagnosed between 1992 and 2016. Patients were divided into four groups according to International Obesity Task Force (IOTF) childhood BMI cut‐offs: underweight, 2.Results: In Cox multivariate regression analyses, an increased risk of relapse was observed in children aged 10‐17.9 years with unhealthy BMI at diagnosis (underweight hazard ratio HR: 2.90 [95% confidence interval: 1.24‐6.78], P = .01; overweight, HR: 1.95 [1.11‐3.43], P = .02, and obese HR: 4.32 [95% 2.08‐8.97], P < .001), compared to children with healthy weight. BMI had no impact on relapse in children under 10 years of age.Conclusion: High BMI, and especially obesity at diagnosis, is an independent adverse prognostic factor for relapse in older children with ALL.


  • Effect of Fish Oil Supplementation on Hyperlipidemia during Childhood Acute Lymphoblastic Leukemia Treatment – A Pilot Study

    by Renate D. Laumann, Turid Iversen, Pernille R. Mogensen, Lotte Lauritzen, Christian Mølgaard, Thomas L. Frandsen

    Hyperlipidemia is common during contemporary treatment of childhood acute lymphoblastic leukemia and may increase risk of osteonecrosis, thrombosis, and possibly acute pancreatitis. Marine fatty acids found in fish oil decrease levels of triglycerides and possibly total cholesterol in hyperlipidemic patients. This prospective pilot study provided fish oil for 83 days to seven children undergoing acute lymphoblastic leukemia treatment. On average fish oil was consumed 74% of the intervention period. Further, we found significant lower levels of triglycerides (P = 0.016) and total cholesterol (P = 0.027) compared to 22 historical controls, although correction for one extra PEG-asparaginase dose reduced the level of significance. However, the findings indicate that fish oil may alleviate development of hyperlipidemia during acute lymphoblastic leukemia treatment. Randomized controlled trials are warranted to confirm these findings and to investigate the potential effect of fish oil supplements on development of severe adverse events, including osteonecrosis, thrombosis, and acute pancreatitis.


  • Open Access

    Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia

    by Pernille Rudebeck Mogensen, Kathrine Grell, Kjeld Schmiegelow, Ulrik Malthe Overgaard, Benjamin Ole Wolthers, Signe Sloth Mogensen, Allan Vaag, Thomas Leth Frandsen

    As survival of acute lymphoblastic leukemia (ALL) exceeds 90%, limiting therapy-related toxicity has become a key challenge. Cardio-metabolic dysfunction is a challenge during and after childhood ALL therapy. In a single center study, we measured triglycerides (TG), total cholesterol (TC), high (HDL) and low density lipoproteins (LDL) levels at diagnosis and assessed the association with BMI, early therapy response, on-therapy hyperlipidemia and the toxicities; thromboembolism, osteonecrosis and pancreatitis. We included 127 children (1.0–17.9 years) all treated according to the NOPHO ALL2008 protocol. Dyslipidemia was identified at ALL-diagnosis in 99% of the patients, dominated by reduced HDL levels (98%) and mild hypertriglyceridemia (61%). Hypertriglyceridemia was not associated with body mass index (P = 0.71). Five percent of patients had mild hypercholesterolemia, 14% had mild hypocholesterolemia, 13% had decreased and 1% elevated LDL-levels. Increased TG and TC levels at ALL-diagnosis were not associated with any on-therapy lipid levels. Lipid levels and BMI were not associated to MRD after induction therapy; However, BMI and hypercholesterolemia were associated with worse risk group stratification (P<0.045 for all). The cumulative incidence of thromboembolism was increased both for patients with hypo- (20.0%) and hypercholesterolemia (16.7%) compared to patients with normal TC levels (2.2%) at diagnosis (P = 0.0074). In conclusion, dyslipidemic changes were present prior to ALL-therapy in children with ALL but did not seem to affect dysmetabolic traits during therapy and were not predictive of on-therapy toxicities apart from an association between dyscholesterolemia at time of ALL-diagnosis and risk of thromboembolism. However, the latter should be interpreted with caution due to low number in the groups.


  • Insulin‐dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia

    by Benjamin Ole Wolthers, Pernille R. Mogensen, Thomas L. Frandsen, Jonas Abrahamsson, Mikael Behrendtz, Mats Heyman, Olli Lohi, Ulrika Norén‐Nyström, Ellen Ruud, Kjeld Schmiegelow

    Pancreatitis is a frequent toxicity to acute lymphoblastic leukemia (ALL) treatment, significantly associated with asparaginase use, and may be followed by severe complications such as acute hyperglycaemia, need for mechanical ventilation, pseudocysts, and death. Here, we provide novel data on seven patients diagnosed with diabetes after pancreatitis and still requiring insulin treatment after a median follow‐up of 4.2 years (range: 1.7–9.2). We describe the clinical course of pancreatitis and illustrate the association between pancreatic pseudocysts, older age, and development of insulin‐dependent diabetes. Together, this study documents the persisting burden of pancreatitis in childhood ALL and underlines the need for plasma glucose level monitoring.


  • Association between body mass index and pancreatitis in children with acute lymphoblastic leukemia

    by Pernille R. Mogensen, Benjamin O. Wolthers, Kathrine Grell, Kjeld Schmiegelow, Thomas L. Frandsen